Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03931109 · ClinicalTrials.gov registry record
Circulating miRNA in Primary Hyperparathyroidism
A clinical trial of Osteoporosis, Postmenopausal and Primary Hyperparathyroidism, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 96
- Enrollment target
- 1
- Study location
NCT03931109 is a study of Osteoporosis, Postmenopausal and Primary Hyperparathyroidism that has completed, run by University of Pennsylvania. The registered enrollment target is 96 participants, below the 3,250-participant average among 10 other Osteoporosis, Postmenopausal trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03931109, a study of Osteoporosis, Postmenopausal and Primary Hyperparathyroidism, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to: 1. Analyze the expression levels of circulating (serum) miRNAs in primary hyperparathyroidism patients with and without osteoporosis, and patients with osteoporosis undergoing thyroidectomy, and to correlate with clinical markers of bone remodeling including biochemical and radiologic studies. 2. To evaluate serum miRNA levels after treatment with parathyroidectomy.
Conditions Studied
Study Locations (1)
Pennsylvania
- Perelman Center for Advanced Medicine/ Hospital of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2018-09-07 |
| Est. Completion | 2024-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03931109
The ClinicalTrials.gov registry entry for NCT03931109 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,250-participant average among 10 other Osteoporosis, Postmenopausal trials with a reported enrollment target (97% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Osteoporosis, Postmenopausal appearing as the primary indexed condition, and to 0 interventions.
NCT03931109 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03931109 about?
NCT03931109 is a clinical study titled "Circulating miRNA in Primary Hyperparathyroidism". The goal of this study is to: 1. Analyze the expression levels of circulating (serum) miRNAs in primary hyperparathyroidism patients with and without osteoporosis, and patients with osteoporosis undergoing thyroidectomy, and to correlate with clinical markers of bone remodeling including biochemical...
What is the current status of trial NCT03931109?
This trial is currently completed. The enrollment target is 96 participants. The study started on 2018-09-07. Estimated completion is 2024-07-01.
What conditions does trial NCT03931109 study?
This clinical trial studies the following conditions: Osteoporosis, Postmenopausal, Primary Hyperparathyroidism.
Who is sponsoring clinical trial NCT03931109?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03931109 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis, Postmenopausal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanisms of Anabolic Osteoporosis Therapy
RECRUITING · NA
-
Combined Anabolic Therapy
RECRUITING · Phase 4
-
Comparative Efficacy, Safety, PK, and Immunogenicity Study
ACTIVE NOT RECRUITING · Phase 3
-
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
ACTIVE NOT RECRUITING · Phase 4
-
Romosozumab Use to Build Skeletal Integrity
ACTIVE NOT RECRUITING · Phase 4
-
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
ACTIVE NOT RECRUITING · Phase 4
Explore more on PlainTrial
Osteoporosis, Postmenopausal
All registered trials for this condition
Primary Hyperparathyroidism
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.